# ALLO — Allogene Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ALLO  
**Sources:** 27  
**Published:** 2026-10-23  
**Canonical:** https://app.k3vl4r.com/research/deep-research-allo-allogene-therapeutics-inc-catalysts-narrative-risks-8711

---

## Company Snapshot

Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a clinical-stage biotechnology company headquartered in South San Francisco developing allogeneic ("off-the-shelf") chimeric antigen receptor (CAR) T cell products—marketed as "AlloCAR T"—for blood cancers, solid tumors, and autoimmune disease [[1]](https://www.marketbeat.com/earnings/reports/2026-11-5-allogene-therapeutics-inc-stock/) [[4]](https://allogene.com/) [[20]](https://stockanalysis.com/stocks/allo/). It was founded in 2018, with founders including David Chang and Arie Belldegrun [[1]](https://www.marketbeat.com/earnings/reports/2026-11-5-allogene-therapeutics-inc-stock/) [[25]](https://allogene.com/about-us/). As of ~October 22, 2026, ALLO traded near $1.25–1.33, with a market capitalization around $432 million and roughly 345 million shares outstanding [[19]](https://finance.yahoo.com/quote/ALLO/) [[20]](https://stockanalysis.com/stocks/allo/). The stock has a 52-week range of $1.04–$4.46 and a beta of 0.56 [[19]](https://finance.yahoo.com/quote/ALLO/) [[20]](https://stockanalysis.com/stocks/allo/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-allo-allogene-therapeutics-inc-catalysts-narrative-risks-8711 (free to sign up)._
